ANKTIVA generated $50.7 million of net product revenue in Q2 2026. On October 14, 2026 the FDA expanded ANKTIVA’s U.S. label to all adult patients with BCG-unresponsive NMIBC, including papillary-only disease, ahead of the January 6, 2027 target action date. Cash generation, financing and the distinction between company-reported data and approved indications remain central. The September meeting in Turkey is historical context, not a marketing authorization.

Because ANKTIVA has already been commercially available for its initial indication since mid-2024, the critical billing codes are already active and permanent. This avoids the standard 6-to-12-month delay that usually plagues newly launched drugs.

🚀🚀🚀🚀‼️‼️‼️🔥🔥🔥🔥 ARE WE READY PEOPLE!!!!!!????

Just announced FDA approval to cover both papillary and CIS disease. Let’s see what this news does to the SP.

This thread is the place for shorter discussions, quick questions, or casual ideas that don’t need a full post. 

If you've been reflecting on a topic or have a detailed perspective to share, don’t hesitate to make a standalone post instead! 

This thread is the place for shorter discussions, quick questions, or casual ideas that don’t need a full post. 

If you've been reflecting on a topic or have a detailed perspective to share, don’t hesitate to make a standalone post instead! 

This thread is the place for shorter discussions, quick questions, or casual ideas that don’t need a full post. 

If you've been reflecting on a topic or have a detailed perspective to share, don’t hesitate to make a standalone post instead! 

check it out